Peptide therapeutics are described as entering a golden age, a claim built on the shift from simple amino acid sequences to cyclic, stapled, and conjugated constructs. This article explains the synthesis chemistry behind that shift, what an integrated chemistry, manufacturing, and controls CMC…
The claim that peptide therapeutics are entering a golden age is best read as a statement about manufacturing, not marketing. The molecules entering development today are structurally far more complex than those of a decade ago, yet the chemistry needed to make them has become reliably achievable. Peptides occupy a narrow chemical territory between small molecules and biologics: they can match the target selectivity of a protein while remaining accessible to synthetic chemistry. That combination is why developers keep returning to them, and why the field's current momentum deserves scrutiny rather than dismissal.
The phrase itself comes from Simon Tyler, co-founder and chief commercial officer of CatSci, in an interview published on September 11, 2025. Tyler's argument rests on three observations. Synthesis technology has advanced to the point where "what was complex 10 years ago is not complex now," in his words. Peptide candidates have moved from naturally occurring amino acid sequences to highly engineered constructs, driven by breakthroughs in synthesis technology alongside a deeper understanding of what peptides can do therapeutically. And success with those constructs depends on an integrated chemistry, manufacturing, and controls CMC approach, not on synthesis alone. He attributes the sector's momentum to the convergence of scientific innovation, market demand, and advanced manufacturing capability.
The three claims have different evidentiary status. That synthesis has gotten easier is consistent with a decade of method development in solid-phase chemistry, and the technical reasons are concrete. That candidates are more complex is visible in the modality classes now common in development pipelines. That integrated CMC is the deciding factor is an operating thesis shared by many peptide process chemists, but the interview offers no comparative data showing that CMC integration separates successful programs from failed ones.
There is also a clinical logic behind the structural escalation. Peptides historically struggled with three weaknesses: rapid proteolytic degradation, fast renal clearance, and poor membrane permeability. Each modern modification exists to fix one of those. Cyclization and backbone N-methylation resist proteases and, in some cases, improve permeability. Stapling locks in an active conformation and slows degradation. Conjugation to a fatty acid, polyethylene glycol, or a targeting payload extends half-life or adds a second function. The golden age is, in part, the moment when these fixes became manufacturable rather than merely conceivable.
Solid-phase peptide synthesis SPPS has been the workhorse method for decades, and its practical ceiling has moved steadily outward. The standard route assembles a peptide from C-terminus to N-terminus on an insoluble resin, using Fmoc-protected amino acids, an activating reagent to drive each coupling, and piperidine to remove the Fmoc group between cycles. The ceiling is chemical, not mechanical. Incomplete couplings leave deletion sequences. Hindered residues couple slowly. Long hydrophobic stretches aggregate on the resin. Side reactions such as oxidation, deamidation, and aspartimide formation contaminate the product. A decade ago, a long synthesis with several difficult junctions was a project that consumed weeks. Today a comparable synthesis runs unattended on automated instruments, and the main question is what the purification will cost.
Several specific advances account for the shift, and it is worth naming them because the interview does not. Microwave-assisted SPPS shortens cycle times and disrupts on-resin aggregation, which improves coupling efficiency for difficult sequences. Resin technology moved from cross-linked polystyrene to polyethylene glycol-based architectures that swell better and present more accessible reaction sites. Coupling chemistry improved: carbodiimide activation combined with oxyma-based additives suppresses racemization, and newer coupling reagents react faster and more fully. Flow-based peptide synthesis, which passes the resin through a packed column rather than stirring it in a batch vessel, dramatically reduces cycle times compared with batch operation and has moved from research novelty to practical method. None of these is a single breakthrough. Their convergence lowered the difficulty barrier.
The consequence is that the bottleneck in peptide development has moved downstream. Making a difficult sequence is no longer the hardest problem. Purifying it, characterizing its impurities, proving that the process is reproducible, and scaling it to commercial quantities are now the binding constraints. This is the technical basis for the insistence that synthesis alone is not sufficient: the expertise that matters has shifted toward what happens after the couplings are done.
Scale economics reinforce the point. Peptide yield falls as length and difficulty rise, and the cost of goods at commercial scale is dominated by raw materials and preparative chromatography, not by instrument time. A synthesis that works in the research lab can be commercially hopeless if its impurity profile forces repeated purification passes. Process chemistry, meaning the deliberate design of the route and the purification train to minimize impurity burden, is what separates a publishable synthesis from a commercial drug substance.
Routine is not the same as trivial. Difficult sequences still need experienced hands, and some constructs fail on the first attempt. The change is that failure is now the exception rather than the default, and when a synthesis does fail, the cause is usually identifiable: a specific difficult coupling, an aggregation-prone segment, or a side reaction that analysis can pinpoint. That diagnostic ability, the pairing of synthesis with analytical feedback, is itself part of what the field now treats as standard capability.
A useful way to see the change is to compare the construct classes now common against their linear predecessors. Each imposes a distinct chemistry and a distinct CMC burden.
| Construct class | What is added | Why it is used | Main difficulty at scale |
|---|---|---|---|
| Cyclic peptide | Head-to-tail amide, disulfide, or thioether link | Rigid conformation, exopeptidase resistance, often better affinity | Favoring intramolecular cyclization over oligomerization |
| Stapled peptide | Hydrocarbon bridge across an alpha helix | Stabilized helix, protease resistance, possible cell entry | Non-natural residues, ring-closing metathesis, diastereomer removal |
| Conjugated peptide | Lipid, PEG, or payload attached covalently | Half-life extension, targeting, potency | Linker stability, control of substitution, purification |
Cyclic peptides are the oldest and most commercially proven of the three. Head-to-tail cyclization joins the peptide's own termini, typically by anchoring a side chain to the resin, activating the C-terminus, and closing the ring intramolecularly. The reaction is concentration-sensitive: at high concentration, intermolecular coupling competes and produces dimers and oligomers that must be removed. Backbone N-methylation, a feature of natural products such as cyclosporine A, can improve permeability and metabolic stability, but couplings at N-methylated residues are sterically hindered and prone to epimerization. Regulatory-grade cyclic peptides therefore demand careful control of cyclization conditions and thorough impurity analysis of the cyclic product.
Stapled peptides are the most engineered of the three. Two non-natural amino acids bearing olefin side chains are placed at i and i+4 or i+7 positions along a helix, and ring-closing metathesis forms a hydrocarbon staple across one face of the helix. The staple locks the peptide into its bioactive alpha-helical conformation, improves protease resistance, and can support cell entry, which is what makes intracellular protein-protein interaction targets accessible to peptides at all. The scale-up chemistry is demanding. The non-natural residues must be sourced or synthesized. The metathesis must proceed cleanly on resin without damaging sensitive residues. The new chiral centers create diastereomers that chromatography must resolve. Stapled peptides remain an active process-development problem rather than a settled routine.
Conjugated peptides carry a covalently attached functional group: a fatty acid for albumin binding and extended half-life, polyethylene glycol for reduced clearance, or a cytotoxic payload for a peptide-drug conjugate. The most commercially visible examples are the fatty-acylated glucagon-like peptide-1 receptor agonists used in metabolic disease, whose acyl chains are connected through linkers and spacers that are themselves the product of careful design. The CMC problem combines the peptide's own impurity profile, the linker's chemical stability, and the stoichiometry and position of the attachment. The team must prove that every batch has the correct attachment site, the correct number of attachments, and no hydrolyzed or rearranged linker, which requires analytical methods capable of distinguishing closely related species.
The classes also combine. A single candidate can be a macrocyclic peptide carrying a lipid tail, or a stapled helix conjugated to a targeting group, and each added feature multiplies the impurity space and the analytical burden. None of these classes is new in concept. Cyclic peptides reached the clinic decades ago, and chemists have designed stabilized helices for almost as long. What has changed is the willingness of developers to build programs around such molecules because manufacturers can now make them reproducibly. This is the real content of the golden age claim: not that a new kind of molecule has been invented, but that the gap between what medicinal chemists can design and what process chemists can manufacture has narrowed.
Chemistry, manufacturing, and controls is the discipline that turns a synthetic route into a reproducible, well-characterized product. For a peptide, three facts make CMC harder than for a typical small molecule. The product is assembled by repetition of a single coupling-deprotection cycle, so errors accumulate along the chain and every batch carries a family of deletion sequences. The product is a mixture of closely related species with nearly identical retention behavior, which pushes chromatography to its limits. And the product is often structurally modified in ways that create new chiral centers and linkage isomers, each of which must be controlled.
Integrated means the components are designed together rather than sequenced. The route chosen in the chemistry lab is selected with an eye to what the manufacturing plant can execute. Analytical methods are developed against the impurities the route actually generates, not against a generic peptide method. The control strategy, meaning the specifications and in-process tests that define a releasable batch, is drafted before the process is locked, not after. The stability program is designed around the degradation pathways that matter for the structural class in question: deamidation at asparagine, oxidation at methionine and cysteine, aspartimide formation, disulfide shuffling in cyclic peptides, and hydrolysis of ester or linker bonds in conjugates.
Three capabilities separate a functioning peptide CMC group from a synthesis service. The first is analytical depth: reverse-phase HPLC that can resolve deletion sequences from the full-length product, high-resolution mass spectrometry for identity and modification mapping, and peptide mapping to localize where a modification occurred. The second is impurity science: the ability to identify an unknown peak as a deletion sequence, an epimer, an oxidation product, or an aggregate, and then to change the route to suppress it. The third is scale-up experience with the specific structural class. A team that has scaled cyclic peptides knows how to manage dilution, temperature, and base strength to favor the intramolecular reaction. A team that has scaled conjugates treats the linker as a critical raw material with its own specifications, sourcing, and stability data.
Regulatory expectations for peptides sit between the small-molecule and biologic frameworks, and they are not static. Agencies expect the same thoroughness of characterization and control that applies to any drug substance, adapted to the molecule's complexity. For a cyclic or conjugated peptide, that means demonstrating that the modification is at the intended site, that the impurity profile is understood and controlled, and that the process is reproducible across batches and scales. Phase-appropriate development matters: early clinical material need not be made on the final commercial route, but the control strategy should be built incrementally from the first batch so that the regulatory submission rests on accumulated data rather than on a late-stage process redesign.
Cost behaves differently for peptides than for small molecules. Purification dominates the cost of goods, so a partner's chromatography capacity and experience with preparative separations matter as much as its reactors. For conjugated peptides, the economics of the linker, spacer, and payload supply chain are part of the process, and a team that cannot control those inputs will struggle to control the product. Buyers should treat the supply chain for non-standard building blocks as a CMC question, not a purchasing question.
For a buyer, the practical implication is that synthesis capacity is table stakes. The differentiating questions are about CMC infrastructure, and the useful ones are concrete.
The interview identifies the problem correctly but does not specify the solution. The following questions separate a partner with integrated CMC capability from a partner that merely makes peptides.
An integrated CMC strategy also implies a specific posture toward time. Peptide process development is iterative, and early material made on a research route is rarely representative of commercial material because impurity profiles shift with scale and equipment. Teams that wait until late development to think about manufacturability inherit a process that may not scale. Teams that run early candidates through scale-down models, and that track impurity fate from the first gram-scale batch, build the dataset that makes the regulatory submission straightforward. The interview's central operational claim is correct: successful programs treat chemistry, manufacturing, and controls as one system from the start.
The golden age framing should be labeled for what it is: an opinion offered by an experienced industry figure in an interview published on September 11, 2025, as part of a vendor's thought-leadership content. It is not a measured fact. The interview supplies no market size, no growth rate, no clinical trial counts, and no data on specific product successes. The claim that peptides have moved from a niche modality to the forefront of drug development is plausible and consistent with the commercial weight of peptide-based metabolic drugs, but the interview does not document it.
The comparison embedded in "what was complex 10 years ago is not complex now" is the best-supported statement in the piece, precisely because it does not require market data. It can be checked against the experience of any process lab that has worked across both eras, and the chemistry above explains why it is true: automation, resin technology, activation chemistry, and flow methods genuinely moved the difficulty curve. Note what the claim does not say. It says the chemistry is no longer complex, not that the product is no longer complex. The constructs themselves remain hard to purify, characterize, and scale, which is why integrated CMC is the centerpiece of the argument.
What remains unresolved is mostly about evidence and scale. Which specific synthesis advances most deserve credit for the shift is not identified, and the honest answer is that a convergence of improvements, rather than a single breakthrough, is responsible. What integrated CMC looks like in practice for a particular program cannot be settled in an interview; it lives in batch records, method validation protocols, and process development labs. Whether stapled and multi-functional conjugated peptides can be manufactured at commercial scale, at acceptable cost and with controlled impurity profiles, is an open empirical question. Regulatory expectations for the newer modalities are still being refined, which is itself a reason to choose a partner with filing experience.
The reasonable position for a researcher or buyer is to treat the optimistic framing as a reason to look carefully, not as a conclusion to adopt. Three statements are supported by the chemistry: peptide candidates are getting more complex, making them is easier than it was, and the limiting factor has moved to CMC capability. The broader prediction of major new opportunities to address unmet patient needs is plausible but unquantified, and it depends on manufacturing economics as much as on science. The question worth answering with your own data is not whether peptides are entering a golden age. It is whether your chemistry, analytics, and manufacturing controls can handle the constructs you are actually designing.
Peptides referenced: Glucagon, GLP-1.
Related reading: Minimizing Aggregation in Protein A Elution: pH and Buffer, Bio-Works Targets Peptide and Oligonucleotide Purification Growth, Fatty-Acyl CGKRK Peptide Improves Chitosan siRNA Delivery In Vitro, Stapled Antimicrobial Peptides: How They Work and What Is Proven.